| Literature DB >> 27097789 |
U C Lalji1, I P L Houben2, R Prevos2, S Gommers2, M van Goethem3, S Vanwetswinkel2, R Pijnappel4, R Steeman2, C Frotscher2, W Mok2, P Nelemans5, M L Smidt6, R G Beets-Tan2,7, J E Wildberger2,7, M B I Lobbes2.
Abstract
OBJECTIVES: Contrast-enhanced spectral mammography (CESM) is a promising problem-solving tool in women referred from a breast cancer screening program. We aimed to study the validity of preliminary results of CESM using a larger panel of radiologists with different levels of CESM experience.Entities:
Keywords: Breast cancer; CEDM; CESM; Contrast-enhanced dual energy mammography; Contrast-enhanced spectral mammography
Mesh:
Substances:
Year: 2016 PMID: 27097789 PMCID: PMC5101272 DOI: 10.1007/s00330-016-4336-0
Source DB: PubMed Journal: Eur Radiol ISSN: 0938-7994 Impact factor: 5.315
Patient characteristics: age, final diagnosis for malignant and benign lesions and subtypes of invasive cancers given
| Age | Years |
| Mean | 58.4 |
| Standard deviation | 8.1 |
| Range | 49–75 |
| Final Diagnosis | Percentage ( |
| Malignant | |
| Invasive ductal carcinoma | 22.1 |
| Invasive lobular carcinoma | 4.0 |
| Ductal carcinoma in situ | 2.5 |
| Invasive mucinous carcinoma | 0.5 |
| Invasive micropapillary carcinoma | 0.5 |
| Benign | |
| Fibroadenoma | 5.5 |
| Simple cyst | 19.1 |
| Reactive changes / benign | 1.5 |
| Apocrine changes / metaplasia | 3.5 |
| Papilloma | 1.5 |
| Superposition | 28.1 |
| Cillindrical cell changes | 2.0 |
| Old hematoma | 0.5 |
| Inflammation | 0.5 |
| Intramammary lymphnode | 2.0 |
| Sclerosing adenosis | 1.0 |
| Atypical lobular hyperplasia | 0.5 |
| Ductectasia | 1.0 |
| Fibrosis | 1.5 |
| Ductal hyperplasia | 1.0 |
| Lobular carcinoma in situ | 0.5 |
| Flat epithelial atypia | 0.5 |
| Total | 100.0 |
| Invasive breast cancer subtypes | Percentage of all invasive cancers |
| ER positive | 92.3 |
| PR positive | 80.8 |
| HER2/neu positive | 12.2 |
| Grade 1 | 27.3 |
| Grade 2 | 47.3 |
| Grade 3 | 25.5 |
ER: estrogen receptor, PR: progesterone receptor, HER2/neu: Human Epidermal growth factor Receptor 2
Diagnostic performance of FFDM and CESM for all ten readers. Diagnostic performance parameters were presented as percentages with 95 % confidence intervals in parentheses
| Reader | Exam | Sensitivity | Specificity |
|---|---|---|---|
| Experienced CESM Reader 1 |
| 86.4 % (75.0–93.9 %) | 67.1 % (58.7–74.8 %) |
|
| 93.2 % (83.5–98.1 %) | 86.4 % (79.6–91.6 %) | |
| Experienced CESM Reader 2 |
| 96.6 % (88.2–99.4 %) | 26.4 % (19.3–34.5 %) |
|
| 98.3 % (90.8–99.7 %) | 70.7 % (62.4–78.1 %) | |
| Experienced CESM Reader 3 |
| 94.9 % (85.8–98.9 %) | 49.3 % (40.7–57.8 %) |
|
| 100.0 % (93.8–100.0 %) | 75.7 % (67.7–82.6 %) | |
| Experienced CESM Reader 4 |
| 98.3 % (90.8–99.7 %) | 15.0 % (9.5–22.0 %) |
|
| 100.0 % (93.8 %–100.0 %) | 75.7 % (67.7–82.5 %) | |
| Mean FFDM | 94.1 % (89.6–98.5 %) | 39.5 % (19.7–59.2 %) | |
| Mean CESM | 97.6 % (95.1–100 %) | 77.1 % (71.5–82.7 %) | |
| Non-Experienced CESM Reader 1 |
| 98.3 % (90.8–99.7 %) | 37.8 % (29.8–56.4 %) |
|
| 100.0 % (93.8–100.0 %) | 67.1 % (58.7–74.8 %) | |
| Non-Experienced CESM Reader 2 |
| 96.6 % (88.2–99.5 %) | 21.4 % (14.9–29.1 %) |
|
| 94.9 % (85.8–98.8 %) | 64.3 % (55.7–72.2 %) | |
| Non-Experienced CESM Reader 3 |
| 89.9 % (79.1–96.1 %) | 40.7 % (32.5–49.3 %) |
|
| 93.2 % (83.5–98.1 %) | 72.8 % (64.7–80.0 %) | |
| Mean FFDM | 94.9 % (90.8–99.0 %) | 33.3 % (23.7–42.9 %) | |
| Mean CESM | 95.9 % (92.9–98.9 %) | 68.0 % (64.1–72.1 %) | |
| Resident |
| 89.8 % (79.1–96.1 %) | 32.8 % (25.1–41.3 %) |
|
| 96.6 % (88.2–99.4 %) | 58.5 % (49.9–66.8 % | |
| Resident |
| 93.2 % (83.5–98.0 %) | 36.4 % (36.4–44.9 %) |
|
| 96.6 % (88.2–99.4 %) | 64.2 % (55.7–72.2 %) | |
| Resident |
| 86.4 % (75.0–93.9 %) | 32.1 % (24.5–40.5 %) |
|
| 96.6 % (88.2–99.5 %) | 61.4 % (52.8–69.5 %) | |
| Mean FFDM | 89.8 % (79.2–96 %) | 33.7 % (28.6–42.2 %) | |
| Mean CESM | 96.6 % (95.4–98.2 %) | 61.3 % (52.8–69.5 %) | |
| All Readers Mean |
| 93.0 % (90.3–95.8 %) | 35.9 % (27.3–44.5 %) |
|
| 96.9 % (93.2–100.0 %) | 69.7 % (64.8–74.6 %) |
Fig. 1Average ROC curves for all readers (a), experienced CESM readers (b), experienced FFDM readers (c) and resident readers (d). AUC values for FFDM and CESM given with confidence intervals in parenthesis. Differences in AUC between FFDM and CESM were significantly increased for all subgroup of reader panels, p-values given per subgroup of reader panel
Difference (∆) in sensitivity and specificity of CESM and FFDM with 95 % confidence intervals (CI) in parenthesis. p values < 0.05 are considered significant
| ∆ Sensitivity CESM-FFDM (95 % CI) |
| ∆ Specificity CESM-FFDM (95 % CI) |
| |
|---|---|---|---|---|
| Experienced CESM readers | 0.035 (-0.009–0.079) |
| 0.376 (0.193–0.559) |
|
| Non-experienced CESM readers | 0.010 (0.036–0.056) |
| 0.348 (0.254–0.442) |
|
| Resident Readers | 0.068 (0.016–0.120) |
| 0.276 (0.223–0.329) |
|
| All readers | 0.038 (0.018–0.058) |
| 0.338 (0.267–0.409) |
|
CESM false negative findings
Diagnosis of false negative cases and the number of readers that scored them as false negative. Experience level is indicated of the number of readers that missed the lesion on CESM. In addition, lesion characteristics such as diameter (given in millimetres), histologic grade, DCIS grade and hormonal receptor status (ER, PR, HER2NEU) are given. Hormone receptor status in case of pure DCIS is not evaluated and therefore not available (n/a) for these cases
| Final diagnosis | Number of readers scoring false negative | Tumour Characteristics | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Histology | Experienced CESM | Non- experienced CESM | Resident | Total | Diameter in mm | Grade | ER | PR | HER2/neu |
| Invasive ductal carcinoma | 1 | 2 | 2 | 5 | 14 | 2 | + | + | - |
| Invasive ductal carcinoma | 1 | 1 | 1 | 3 | 22 | 2 | + | + | + |
| Invasive mucinous carcinoma | - | 2 | - | 2 | 18 | 1 | + | + | - |
| Invasive ductal carcinoma | - | 1 | - | 1 | 20 | 2 | + | - | - |
| Invasive ductal carcinoma | 1 | - | - | 1 | 7 | 1 | + | + | - |
| Invasive ductal carcinoma | 1 | - | - | 1 | 4 | 1 | + | - | - |
| Invasive ductal carcinoma | - | - | 1 | 1 | 16 | 2 | + | + | - |
| Ductal carcinoma in situ | - | 1 | - | 1 | 10 | 2-3 | n/a | n/a | n/a |
| Invasive lobular carcinoma | - | - | 1 | 1 | 5 | 2 | + | + | - |
| Ductal carcinoma in situ | - | - | 1 | 1 | 26 | 3 | n/a | n/a | n/a |
Fig. 2Overview of number of cases and diagnosis of false-positive findings. These cases were scored as false-positive cases by five or more readers
Studies comparing CESM and Mammography: number of patients included, sensitivity and specificity given for CESM
| Study | Number of patients ( | Sensitivity (%) | Specificity (%) | Disease prevalence (%) |
|---|---|---|---|---|
| Lewin et al. [ | 26 | 100 | 86.7 | 50 |
| Dromain et al. [ | 144 | 93 | 63 | 56.3 |
| Dromain et al. [ | 110 | 91.9 | 46 | 56.7 |
| Fallenberg et al. [ | 80 | 100 | - | 100 |
| Jochelson et al. [ | 52 | 96 | - | 100 |
| Fallenberg et al. [ | 118 | 94.7*/95** | - | 100 |
| Lobbes et al. [ | 113 | 100 | 87.7 | 28 |
| Luczyńska et al. [ | 152 | 100 | 41 | 76 |
| Cheung et al. [ | 89 | 92.7 | 67.9 | 72 |
| Luczyńska et al. [ | 118 | 100 | Not provided | 68.6 |
| Cheung et al. [ | 52 | 90.9 | 83.78 | 37.7 |
Disease prevalence based on number of lesions analysed in the included population is given, calculated from data given in study
Annotations: aSensitivity for CESM alone (*) and for CESM in combination with mammography (**). bPatients with microcalcifications only
Fig. 3Example of false negatives cases. Low-energy images at the top with corresponding re-combined images underneath. A: infiltrating grade 2 ductal carcinoma with grade 3 ductal carcinoma in situ (curved arrow), B: invasive grade 2 ductal carcinoma (arrow head) and C: grade 1 mucinous carcinoma (straight arrow)